Botox vs Dysport for Med Spas: Choosing, Pricing, and Marketing Both Neuromodulators

The botox vs dysport med spa debate is one that every practice owner eventually faces. Both are FDA-approved botulinum toxin type A products that temporarily reduce wrinkles by blocking nerve signals to targeted muscles. Both are safe, effective, and in enormous demand. Yet they are not interchangeable — they differ in formulation, diffusion characteristics, onset speed, pricing dynamics, and patient perception in ways that directly affect how you should position, price, and market each one.

For med spa owners, the question is not simply which product is "better." It is how to make the smartest business decision about your neuromodulator comparison strategy: should you offer one or both, how should you price each to maximize margins, and how do you market them to different patient segments? This guide covers the clinical differences that matter for business decisions, pricing strategies that protect your margins, and marketing angles that drive patient acquisition for each product.

1. Clinical Differences That Affect Your Business

Understanding the clinical distinctions between Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) is essential not because you need to become an expert injector overnight, but because these differences directly shape how you price, schedule, and market each product. Your providers likely already know the clinical nuances — what matters for the business side is how those nuances translate to patient experience and revenue.

Onset and Duration

Dysport typically shows visible results within 2-3 days, compared to 3-5 days for Botox. Full effect for both products develops over 10-14 days. This faster onset is one of Dysport's most marketable advantages — patients preparing for an event on short notice genuinely benefit from the quicker timeline.

Duration is comparable between the two products, with most patients experiencing 3-4 months of effect. Some studies suggest Dysport may last slightly longer for certain patients, but the difference is not consistent enough to use as a primary marketing claim. What you can say is that individual results vary and that your providers will help determine the optimal product and retreatment schedule for each patient.

Diffusion and Spread

Dysport has a slightly higher diffusion rate than Botox, meaning it spreads more broadly from the injection site. This characteristic makes Dysport particularly effective for large, flat treatment areas like the forehead, where broader diffusion creates a more natural, even result. Conversely, Botox's more precise, localized effect makes it preferable for smaller, targeted areas like crow's feet or brow shaping where controlled placement is critical.

This diffusion difference is not just a clinical talking point — it is a legitimate reason to recommend different products for different treatment areas within the same patient visit. A provider who uses Dysport for the forehead and Botox for crow's feet is practicing evidence-based aesthetic medicine, and that level of customization becomes a powerful marketing differentiator. For more on building a comprehensive service offering, see our treatment menu strategy guide.

Unit Conversion and Dosing

The most important clinical difference for pricing purposes is the unit conversion ratio. One unit of Botox is not equivalent to one unit of Dysport. The generally accepted conversion ratio is 1:2.5 to 1:3, meaning a treatment requiring 20 units of Botox would require 50-60 units of Dysport to achieve comparable results.

This conversion ratio creates both confusion and opportunity. Patients who compare per-unit prices without understanding the conversion will perceive Dysport as dramatically cheaper. You must educate your front desk and marketing team to communicate pricing in terms of treatment areas or outcomes, not raw unit counts, to avoid misperceptions and margin erosion.

2. Pricing Strategies for Maximum Margin

Pricing neuromodulators is one of the most consequential financial decisions in your med spa. Get it right and injectables become your most profitable service line. Get it wrong and you race to the bottom with every competitor running a "Botox special." Your overall pricing strategy should treat neuromodulators as a premium offering, not a commodity.

Per-Unit vs. Per-Area Pricing

There are two primary pricing models for neuromodulators, and the one you choose significantly affects both patient perception and your margins:

Per-unit pricing is the traditional model. You charge a set price per unit — for example, $14-18 per unit of Botox or $5-7 per unit of Dysport. This model is transparent and allows patients to compare prices across practices, but it commoditizes your service, invites price shopping, and makes it harder to differentiate on quality or expertise.

Per-area pricing charges a flat rate per treatment area — for example, $350-500 for the forehead, $250-400 for crow's feet, $200-350 for the glabella (11 lines). This model shifts the conversation from commodity pricing to outcome-based value. Patients focus on the result they want rather than counting units, and your providers can use the clinically appropriate dose without financial pressure to under-treat.

Per-area pricing also elegantly solves the Botox-vs-Dysport price comparison problem. When the forehead costs $400 regardless of which product is used, the conversation becomes about which product your provider recommends for the best result — not which one is cheaper per unit.

Competitive Pricing Without Racing to the Bottom

Every market has a practice running a "$9/unit Botox" promotion, and it is tempting to match. Resist. Competing on price alone attracts price-sensitive patients who will leave the moment someone undercuts you. Instead, compete on value by bundling neuromodulators with complementary services.

• The "Complete Refresh" package: Neuromodulator treatment plus a hydrating facial at a combined price that feels like a deal while maintaining margins on both services
• Loyalty pricing: Maintain standard pricing but offer a meaningful discount (10-15%) for patients who pre-pay for 3 or 4 treatments annually, guaranteeing retention and predictable revenue
• New patient introductory rate: A modest discount (10%) on first-time neuromodulator treatments, positioned as an investment in the relationship rather than a commodity discount
• Membership programs: Monthly subscription plans that include a set number of neuromodulator units per year, creating recurring revenue and dramatically increasing retention

These strategies protect your pricing integrity while still giving value-conscious patients a path to choose you over lower-priced competitors.

Manufacturer Programs and Volume Discounts

Both Allergan (Botox) and Galderma (Dysport) offer loyalty and rewards programs that can meaningfully reduce your cost of goods:

Allergan's Alle program (formerly Brilliant Distinctions) rewards patients with points redeemable toward future Botox, Juvederm, and other Allergan treatments. For your practice, Alle drives repeat business and brand loyalty — patients accumulate points they can only use at participating providers.

Galderma's ASPIRE program offers similar patient rewards for Dysport and Restylane products. Additionally, Galderma tends to be more aggressive with practice-level volume discounts and promotional pricing, particularly for practices willing to commit to purchase volumes.

Carrying both product lines allows you to use each manufacturer's promotions without being locked into a single supplier. When Galderma runs a promotional discount, you can push Dysport. When Allergan enhances the Alle program benefits, you spotlight Botox. This flexibility gives you more pricing tools and better negotiating use with both companies.

3. Patient Preference Trends and Demographics

Understanding which patients prefer which product — and why — allows you to tailor your marketing and consultations for maximum conversion.

Brand Loyalty vs. Outcome Focus

Patient preferences for neuromodulators fall into two broad categories. The first group is brand-loyal: they want Botox specifically because they know the name, their friend recommended it by name, or they have used it before and trust it. This group represents approximately 60-65% of neuromodulator patients and responds to marketing that reinforces Botox's brand recognition and track record.

The second group is outcome-focused: they want wrinkle reduction and are open to whichever product their provider recommends. This group — roughly 35-40% of patients — is where Dysport gains traction. They respond to messaging about personalized treatment plans, clinical expertise, and product selection based on their specific anatomy and goals.

Generational Differences

Age demographics play a meaningful role in product preference. Patients over 45 overwhelmingly request Botox by name — it is the brand they have known for decades. Younger patients (25-40), particularly those discovering neuromodulators through social media, are more open to Dysport and often appreciate being presented with options. This younger demographic also responds well to "insider knowledge" marketing — content that positions Dysport as the option your injector personally prefers or the "industry secret" that savvy patients know about. For more on reaching different age groups, see our guide on generational marketing for med spas.

The "Botox Non-Responder" Opportunity

A small but significant percentage of patients develop antibodies to one botulinum toxin formulation, resulting in diminished results over time. These patients often assume that "Botox stopped working for me" and may stop seeking treatment entirely. A practice that proactively identifies these patients and offers Dysport as an alternative captures revenue that would otherwise be lost. Train your providers to recognize declining treatment efficacy and frame the conversation as: "Your body may be responding differently to this formulation — let us try Dysport, which works through a slightly different mechanism and often produces excellent results for patients in your situation."

4. Marketing Botox vs. Dysport: Positioning and Messaging

How you market each product should reflect its strengths, your target audience, and your competitive positioning. The worst approach is treating them as interchangeable commodities. The best approach gives each product a distinct identity in your marketing.

Marketing Botox: Use the Brand

Botox has something no competitor can replicate: universal brand recognition. "Botox" has become a generic term for wrinkle-reducing injections, much like "Kleenex" for tissues. Your Botox marketing should lean into this brand equity. For a comprehensive approach, see our Botox marketing guide.

• SEO advantage: "Botox near me" generates 10-20x more search volume than "Dysport near me." Your website and blog content should target Botox keywords aggressively because that is what patients search for
• Trust and safety messaging: Botox has the longest track record, the most clinical data, and the deepest consumer trust. Emphasize that your practice uses the "gold standard" neuromodulator
• Premium positioning: Botox's brand recognition supports premium pricing. Patients expect to pay more for Botox and often associate lower prices with lower quality

Marketing Dysport: Differentiation and Education

Dysport marketing requires a different approach — you are introducing many patients to a product they have never heard of, which means education must precede promotion:

• Speed-of-results angle: "See results 2-3 days faster" is Dysport's most strong patient-facing differentiator. Market it to event-driven patients — brides, gala attendees, vacation planners
• Natural results messaging: Dysport's broader diffusion lends itself to "natural-looking" result claims. Marketing that features language like "smooth, natural movement" and "no frozen look" resonates strongly with first-time patients and younger demographics
• Provider-recommended positioning: "Ask your injector about Dysport" or "the neuromodulator our providers choose for themselves" builds credibility through professional endorsement
• Value positioning: Without competing on raw price, you can position Dysport as offering comparable results at a more accessible investment, particularly through per-area pricing

Content Marketing for Both Products

Create separate content paths for each product that address patients at different stages of their decision-making journey:

1. Awareness content: Blog posts and social media comparing the two products educate patients who are researching their options. Titles like "Botox vs. Dysport: What Your Injector Wants You to Know" attract high-intent search traffic
2. Consideration content: Detailed treatment pages for each product on your website, featuring before-and-after galleries (with proper consent), pricing transparency, and provider credentials
3. Decision content: Patient testimonials and case studies showing results from each product. Video content featuring your providers explaining when they recommend each product builds trust and positions your practice as the expert authority

5. Inventory Management and Operational Considerations

Carrying two neuromodulators introduces operational complexity that must be managed proactively to protect margins and avoid waste.

Shelf Life and Waste Prevention

Both Botox and Dysport have shelf-life considerations. Unopened vials have long shelf lives when properly refrigerated (Botox: 36 months, Dysport: 24 months). However, once reconstituted, both products should ideally be used within 24 hours, though many practices store reconstituted product for up to 2 weeks under refrigeration.

The key to minimizing waste is scheduling. Cluster neuromodulator appointments to maximize the use of each reconstituted vial. If you open a vial of Dysport for one patient, make sure you have other Dysport patients scheduled that same day. This is easier in high-volume practices; smaller practices may need to designate specific days as "Dysport days" and "Botox days" to optimize vial utilization.

Staff Training and Product Knowledge

Every patient-facing team member needs to understand the basic differences between the two products, pricing for each, and how to answer common questions without providing medical advice. Your front desk should be able to explain: "Both are excellent options for reducing wrinkles. They work similarly but have some differences in how quickly results appear and how they spread. Your provider will recommend the best option for your specific goals during your consultation."

Providers need deeper training on reconstitution protocols, dosing conversions, injection technique differences, and which product to recommend for specific treatment areas and patient types. Invest in manufacturer-sponsored training programs — both Allergan and Galderma offer excellent injector education, often at no cost.

6. The Strategic Case for Offering Both

After weighing the clinical, financial, and marketing considerations, the strategic case for offering both neuromodulators is strong for most established med spas. Here is a summary of the key advantages:

• Broader patient capture: You serve both brand-loyal Botox patients and outcome-focused patients open to alternatives
• Non-responder retention: Patients who develop tolerance to one product can switch to the other without leaving your practice
• Marketing flexibility: You can run promotions and seasonal campaigns on one product without devaluing the other
• Manufacturer use: Carrying competing products gives you negotiating power on pricing and promotional support
• Revenue per patient: Some patients will use different products for different treatment areas in the same visit, increasing average transaction value
• Competitive differentiation: Offering both products positions your practice as comprehensive and patient-centered, which supports premium positioning

The primary arguments against carrying both — inventory complexity, training requirements, and minimum purchase commitments — are valid but manageable. Most practices find that the revenue upside far outweighs the operational overhead once neuromodulator volume exceeds 30-40 patients per month.

7. Implementation Roadmap: Adding a Second Neuromodulator

If you currently offer only one neuromodulator and are ready to add the second, follow this phased approach to minimize disruption and maximize adoption:

Phase 1: Foundation (Weeks 1-2)

• Establish your account with the second manufacturer and complete initial ordering
• Schedule provider training on reconstitution, dosing, and injection technique for the new product
• Set pricing using per-area pricing to simplify the patient conversation
• Update your consent forms and treatment documentation to include the new product
• Train front desk staff on basic product differences and how to answer patient questions

Phase 2: Soft Launch (Weeks 3-4)

• Begin offering the new product to existing neuromodulator patients as an alternative during their next appointment
• Focus on patients who have expressed dissatisfaction with current results or who are due for a treatment adjustment
• Collect before-and-after photos with consent to build your results gallery
• Create website content: a dedicated treatment page, a comparison blog post, and updated service listings

Phase 3: Full Marketing (Month 2+)

• Launch social media campaigns highlighting the new product's unique benefits
• Run an introductory promotion for new-to-product patients (not a price discount — a value-add like a complimentary consultation or skincare sample)
• Add the new product to your email marketing and patient communication sequences
• Enroll in the manufacturer's patient rewards program and promote it actively
• Track product mix, margins, and patient satisfaction by product to optimize your strategy

Frequently Asked Questions

Make Your Neuromodulator Strategy a Competitive Advantage

The botox vs dysport med spa decision is not a binary choice — it is an opportunity to build a more resilient, profitable, and patient-centered practice. The practices that thrive in an increasingly competitive aesthetic market are those that view their neuromodulator strategy as a comprehensive business decision encompassing product selection, pricing architecture, marketing positioning, and patient education.

Whether you choose to specialize in one product or offer both, the key is intentionality. Set your pricing to protect margins, not win price wars. Market each product based on its genuine strengths, not generic claims. Train your team to educate patients rather than just sell units. And track your product mix data to continuously optimize your strategy.

The neuromodulator market continues to grow every year, with new competitors like Xeomin, Jeuveau, and Daxxify expanding patient options. Med spas that develop sophisticated, data-driven neuromodulator strategies now will be positioned to adapt as the market evolves — while those still competing on per-unit price alone will continue to see their margins erode.